Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

Sung Hee Um1, Francesca Frigerio, Mitsuhiro Watanabe

  • 1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland.

Nature
|August 13, 2004
PubMed

Insights

S6 Kinase 1 (S6K1) deficiency protects against obesity by enhancing fat breakdown. However, S6K1 negatively regulates insulin signaling, particularly under high-fat conditions, offering new therapeutic targets for diabetes.

Area of Science:

  • Metabolic signaling pathways
  • Obesity and diabetes research
  • Mammalian Target of Rapamycin (mTOR) pathway

Background:

  • Obesity impairs insulin action, contributing to diabetes.
  • S6 Kinase 1 (S6K1) integrates nutrient and insulin signals.
  • S6K1 deficiency in mice shows complex metabolic phenotypes, including glucose intolerance and altered insulin sensitivity.

Purpose of the Study:

  • To investigate the role of S6K1 in metabolic regulation and insulin sensitivity.
  • To determine the impact of S6K1 deficiency on obesity and response to high-fat diets.
  • To elucidate the molecular mechanisms linking S6K1 to insulin resistance.

Main Methods:

  • Analysis of S6K1-deficient mice under normal and high-fat diet conditions.
  • Assessment of glucose homeostasis, free fatty acid levels, and beta-oxidation.
  • Investigation of insulin receptor substrate 1 (IRS1) phosphorylation at key insulin resistance sites (S307 and S636/S639).

Main Results:

  • S6K1-deficient mice are protected against diet-induced obesity due to enhanced beta-oxidation.
  • Despite protection, high-fat diets lead to hyperglycemia and insulin receptor desensitization in S6K1-deficient mice.
  • S6K1 deficiency prevents IRS1 phosphorylation at S307 and S636/S639, indicating preserved insulin sensitivity via a disrupted negative feedback loop.
  • Obese wild-type and genetic obesity models exhibit elevated S6K1 activity and increased IRS1 phosphorylation.

Conclusions:

  • S6K1 plays a critical role in negatively regulating insulin signaling under nutrient-rich conditions.
  • Disruption of the S6K1-IRS1 negative feedback loop contributes to insulin sensitivity.
  • Targeting S6K1 activity may offer therapeutic strategies for obesity and type 2 diabetes.

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Other Disorders of Digestive System01:30

Other Disorders of Digestive System

The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Sulfur Assimilation01:20

Sulfur Assimilation

Sulfur is an essential element in biological systems, contributing to synthesizing key biomolecules, including amino acids such as cysteine and methionine, and cofactors such as coenzyme A and biotin. Microorganisms primarily assimilate sulfur as sulfate (SO₄²⁻) from the environment, which must undergo a series of biochemical transformations before it can be incorporated into cellular components. As sulfate is highly oxidized, it must undergo assimilatory sulfate reduction to become...